DNTH
HEALTHCAREDianthus Therapeutics Inc
$90.42+0.18 (+0.20%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving DNTH Today?
No stock-specific AI insight has been generated for DNTH yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$16.64$96.50
$90.42
Fundamentals
Market Cap$4.9B
P/E Ratio—
EPS$-4.23
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin—
Debt / Equity—
Trading
Volume467K
Avg Volume (10D)—
Shares Outstanding54.7M
DNTH News
20 articles- LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and DermatomyositisGlobeNewswire Inc.·May 6, 2026
- Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 5, 2026
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial ResultsYahoo Finance·May 5, 2026
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 1, 2026
- Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Trial Shift And Renewed Analyst OptimismYahoo Finance·Apr 27, 2026
- Dianthus Therapeutics Inc (DNTH): FDA Makes Trials EasierYahoo Finance·Apr 23, 2026
- Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000The Motley Fool·Apr 19, 2026
- Dianthus Therapeutics CFO Sells $9.5 Million in StockThe Motley Fool·Apr 6, 2026
- How Investors May Respond To Dianthus Therapeutics (DNTH) Early “GO” Decision And FDA Backing For ClaseprubartYahoo Finance·Apr 3, 2026
- Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?Yahoo Finance·Apr 1, 2026
- Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDPYahoo Finance·Mar 18, 2026
- Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million ExitMotley Fool·Mar 18, 2026
- Dianthus Therapeutics Hits Early “Go” in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg ArmMarketbeat·Mar 15, 2026
- Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” DecisionYahoo Finance·Mar 13, 2026
- Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesYahoo Finance·Mar 12, 2026
- Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public OfferingYahoo Finance·Mar 11, 2026
- Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH)Yahoo Finance·Mar 10, 2026
- Dianthus Therapeutics Has Appreciated 12-Fold Over Two Years. What's Going On?Yahoo Finance·Mar 9, 2026
- Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public OfferingYahoo Finance·Mar 9, 2026
- Top Midday GainersYahoo Finance·Mar 9, 2026
All 20 articles loaded
Price Data
Open$91.81
Previous Close$90.24
Day High$91.81
Day Low$87.47
52 Week High$96.50
52 Week Low$16.64
52-Week Range
$16.64$96.50
$90.42
Fundamentals
Market Cap$4.9B
P/E Ratio—
EPS$-4.23
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin—
Debt / Equity—
Trading
Volume467K
Avg Volume (10D)—
Shares Outstanding54.7M
About Dianthus Therapeutics Inc
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—